Panacea Biotec Ltd. (NSE: PANACEABIO, BSE: 531349) is a New Delhi, Delhi-based company in the Vaccines and Biologics industry. With a market capitalisation of ₹2,203 Cr, it ranks #1,193 by market cap among the 6,137 Indian listed companies on FinBizNet, and #1 of 2 in Vaccines and Biologics. At ₹311.45 (as of 25 Oct 2026), the share price is 51.9% below its 52-week high of ₹647.00 and 6.5% above its 52-week low of ₹292.40. The share price is down 30.9% over one year and down 29.4% over three months.
| Current Price | ₹311.45 |
|---|---|
| Market Cap | ₹2,203 Cr |
| NSE Symbol | PANACEABIO |
| BSE Code | 531349 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Vaccines and Biologics |
| P/E Ratio | -397.6 |
| Return on Equity | -0.86% |
| Return on Assets | -1.32% |
| 52-Week Range | ₹292.40 – ₹647.00 |
| 1-Year Price Change | -30.9% |
| 3-Month Price Change | -29.4% |
| Beta (1Y) | 0.21 |
| Dividend Yield | 0.00% |
| Headquarters | New Delhi, Delhi |
| Website | www.panaceabiotec.com |
| Revenue | ₹200 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 1.1% |
| EPS (Basic) | ₹0.38 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment
1. Vaccines-This segment researches, develops, manufactures, and markets vaccines. 2. Formulations-This segment researches, develops, manufactures, and markets pharmaceutical formulations. 3. Vaccines - Discontinued Operations-This segment researches, develops, manufactures, and markets vaccines. 4. Real Estate - Discontinued Operations-This segment engages in the real estate business.
1. Vaccines-64.1% 2. Pharmaceutical Formulations & Nutrition-35.9%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Panacea Biotec Ltd. | ₹2,203 Cr | -397.6 | -0.86% | ₹200 Cr | -30.9% |
| Bharat Immunologicals & Biologics Ltd | ₹43 Cr | -2.5 | -17.19% | ₹0 Cr | -29.7% |
Listed by market capitalisation. Ratios are shown for context only.
Panacea Biotec Ltd. is trading at ₹311.45, with a market capitalisation of ₹2,203 Cr.
Panacea Biotec Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Vaccines and Biologics).
Panacea Biotec Ltd. has a P/E of -397.6 and a return on equity of -0.86%.
Panacea Biotec Ltd. is listed on the NSE under the symbol PANACEABIO and on the BSE under the scrip code 531349.
Panacea Biotec Ltd.'s share price is down 30.9% over one year and down 29.4% over three months. Its 52-week range is ₹292.40 to ₹647.00.
In Q1 FY27, Panacea Biotec Ltd. reported revenue of ₹200 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.38 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.